Ann Oncol. 2015 Oct;26(10):2026-33. doi: 10.1093/annonc/mdv256. Epub 2015 Jun 02.

The new therapeutical scenario of Hodgkin lymphoma.

Annals of oncology : official journal of the European Society for Medical Oncology

A Stathis, A Younes

PMID: 26037796 DOI: 10.1093/annonc/mdv256

Abstract

Hodgkin lymphoma (HL) remains one of the most curable human cancers, as modern combination chemotherapy and radiation therapy cure ∼ 80% of patients. Over the last two decades, the major efforts were focused on the development of more intensive front-line regimens for patients with advanced stage HL, decreasing the number of chemotherapy cycles and radiation therapy field and doses for patients with early-stage HL and incorporating positron emission tomography imaging in diagnostic, prognostic, and treatment planning. More recently, the improved knowledge of the molecular biology of the disease led to the development of highly active new agents, including the antibody-drug conjugate brentuximab vedotin and immune checkpoint inhibitors. Accordingly, the current efforts are focusing on incorporating these new agents into standard of care regimens, aiming at further improving cure rates, while reducing treatment-related toxicity. In this review, we will focus on the current status of HL therapy and how the development of new agents is re-shaping standard of care regimens.

© The Author 2015. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: [email protected].

Keywords: HDAC inhibitors; Hodgkin lymphoma; PET response-adapted therapy; brentuximab vedotin; immune checkpoint inhibitors; new treatment combinations

MeSH terms

• Combined Modality Therapy
• Hodgkin Disease / therapy
• Humans
• Molecular Targeted Therapy*
• Prognosis

Publication Types

• Journal Article
• Review